Stock comparison
Halozyme Therapeutics
Veeva Systems
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
VEEV
Veeva Systems
Market cap
$26.07B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | VEEV | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 66B | HALO |
| Benjamin Graham | 83A | 81A | HALO |
| Philip Fisher | 65B | 77B | VEEV |
| Peter Lynch | 53D | 60C | VEEV |
| Joel Greenblatt | 40D | 52C | VEEV |
| Charlie Munger | 80C | 62C | HALO |
| Terry Smith | 84A | 65D | HALO |
Side-by-side metrics
| Metric | HALO | VEEV |
|---|---|---|
| Market cap | $8.1B | $26.07B |
| P/E (TTM) | 24.0x | 28.7x |
| EV/EBIT | 10.2x | 26.9x |
| ROIC (TTM) | 23.65% | 9.48% |
| Gross margin | 81.24% | 75.53% |
| Net margin | 23.13% | 28.44% |
| Revenue CAGR 5y | 33.23% | 14.63% |
| EPS CAGR 5y | -1.98% | 18.76% |
| Debt / Equity | 1.0x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- EV/EBIT10.2xvs 26.9x+62%
- ROIC (TTM)23.65%vs 9.48%+60%
- Revenue CAGR 5y33.23%vs 14.63%+56%
- P/E (TTM)24.0xvs 28.7x+16%
VEEV leads on
- EPS CAGR 5y18.76%vs -1.98%+111%
- Debt / Equity0.0xvs 1.0x+99%
- Market cap$26.07Bvs $8.1B+69%
- Net margin28.44%vs 23.13%+19%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.